FTC: 12- to 14-year exclusivity for biotech drugs too long

06/10/2009 | Reuters

The 12- to 14-year market exclusivity sought by biotech drugmakers to protect their brand name products is too long because it will stifle innovation and chances are these companies will keep "a substantial market share" when generic counterparts gain FDA approval, according to a Federal Trade Commission report. Follow-on biologics are unlikely to be discounted more than 10% to 30% off the price of brand name medicines, according to the report.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR CLINICAL RESEARCH - 14000003MB
Abbott
Santa Clara, CA
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA